272 related articles for article (PubMed ID: 32348295)
1. Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy.
Ai X; Liao X; Wang M; Hu Y; Li J; Zhang Y; Tang P; Jiang J
Med Sci Monit; 2020 Apr; 26():e922420. PubMed ID: 32348295
[TBL] [Abstract][Full Text] [Related]
2. Lymph node counts and ratio in axillary dissections following neoadjuvant chemotherapy for breast cancer: a better alternative to traditional pN staging.
Chen S; Liu Y; Huang L; Chen CM; Wu J; Shao ZM
Ann Surg Oncol; 2014 Jan; 21(1):42-50. PubMed ID: 24013900
[TBL] [Abstract][Full Text] [Related]
3. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
[TBL] [Abstract][Full Text] [Related]
4. Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy.
Wu SG; Chen Y; Sun JY; Li FY; Lin Q; Lin HX; He ZY
Radiat Oncol; 2013 May; 8():119. PubMed ID: 23672513
[TBL] [Abstract][Full Text] [Related]
5. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Kim SH; Jung KH; Kim TY; Im SA; Choi IS; Chae YS; Baek SK; Kang SY; Park S; Park IH; Lee KS; Choi YJ; Lee S; Sohn JH; Park YH; Im YH; Ahn JH; Kim SB; Kim JH
Cancer Res Treat; 2016 Oct; 48(4):1373-1381. PubMed ID: 27034147
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of lymph node ratio in survival of non-metastatic breast carcinoma patients.
Singh D; Mandal A
Breast Cancer Res Treat; 2020 Dec; 184(3):839-848. PubMed ID: 32852709
[TBL] [Abstract][Full Text] [Related]
9. Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy.
Wu SG; Li Q; Zhou J; Sun JY; Li FY; Lin Q; Lin HX; Gaun XX; He ZY
Cancer Res Treat; 2015 Oct; 47(4):757-64. PubMed ID: 25672578
[TBL] [Abstract][Full Text] [Related]
10. Lymph node ratio as an alternative to pN staging for predicting prognosis after neoadjuvant chemotherapy in breast cancer.
Cho DH; Bae SY; You JY; Kim HK; Chang YW; Choi YJ; Woo SU; Son GS; Lee JB; Bae JW; Jung SP
Kaohsiung J Med Sci; 2018 Jun; 34(6):341-347. PubMed ID: 29747778
[TBL] [Abstract][Full Text] [Related]
11. Metastatic axillary lymph node ratio (LNR) is prognostically superior to pN staging in patients with breast cancer--results for 804 Chinese patients from a single institution.
Xiao XS; Tang HL; Xie XH; Li LS; Kong YN; Wu MQ; Yang L; Gao J; Wei WD; Xie X
Asian Pac J Cancer Prev; 2013; 14(9):5219-23. PubMed ID: 24175804
[TBL] [Abstract][Full Text] [Related]
12. Lymph Node Ratio in Sentinel Lymph Node Biopsy Era: Are We Losing Prognostic Information?
Quintyne KI; Woulfe B; Coffey JC; Merrigan A; Gupta RK
Clin Breast Cancer; 2017 Apr; 17(2):117-126. PubMed ID: 27592541
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of metastatic axillary lymph node ratio in node-positive breast cancer treated by breast conserving surgery].
Zheng Y; Chen Q; Liang Z; Jia M; Cao X
Zhonghua Zhong Liu Za Zhi; 2015 Jan; 37(1):41-6. PubMed ID: 25877318
[TBL] [Abstract][Full Text] [Related]
14. Lymph node ratio is an independent prognostic factor in node positive rectal cancer patients treated with preoperative chemoradiotherapy followed by curative resection.
Zeng WG; Zhou ZX; Wang Z; Liang JW; Hou HR; Zhou HT; Zhang XM; Hu JJ
Asian Pac J Cancer Prev; 2014; 15(13):5365-9. PubMed ID: 25041003
[TBL] [Abstract][Full Text] [Related]
15. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer.
van der Wal BC; Butzelaar RM; van der Meij S; Boermeester MA
Eur J Surg Oncol; 2002 Aug; 28(5):481-9. PubMed ID: 12217299
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
Li X; Tan Q; Li H; Yang X
J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
18. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
19. Additional Prognostic Value of Lymph Node Ratio (LNR) and Number of Negative Lymph Nodes (NLNs) in Chinese Patients with Triple Negative Breast Cancer.
Wang QX; Cai YF; Chen YY; Zhang W; Jin WX; Chen ED; Zhang XH; Li Q
Ann Clin Lab Sci; 2017 Jan; 47(1):68-75. PubMed ID: 28249920
[TBL] [Abstract][Full Text] [Related]
20. Additional prognostic value of lymph node ratio over pN staging in different breast cancer subtypes based on the results of 1,656 patients.
Ataseven B; Kümmel S; Weikel W; Heitz F; Holtschmidt J; Lorenz-Salehi F; Kümmel A; Traut A; Blohmer J; Harter P; du Bois A
Arch Gynecol Obstet; 2015 May; 291(5):1153-66. PubMed ID: 25367604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
